Bridge City Capital LLC Sells 2,019 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Bridge City Capital LLC reduced its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 0.9% in the 4th quarter, HoldingsChannel reports. The firm owned 229,196 shares of the company’s stock after selling 2,019 shares during the quarter. Bridge City Capital LLC’s holdings in Pacira BioSciences were worth $4,318,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in PCRX. Caitlin John LLC increased its position in Pacira BioSciences by 1,850.0% in the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after buying an additional 1,776 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in Pacira BioSciences by 495.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $62,000 after acquiring an additional 2,749 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock valued at $68,000 after acquiring an additional 513 shares during the period. Virtus Investment Advisers Inc. bought a new stake in shares of Pacira BioSciences during the third quarter valued at approximately $98,000. Finally, Quest Partners LLC raised its position in shares of Pacira BioSciences by 137.6% during the third quarter. Quest Partners LLC now owns 9,410 shares of the company’s stock worth $142,000 after purchasing an additional 5,449 shares during the period. Institutional investors own 99.73% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on PCRX shares. Truist Financial upgraded shares of Pacira BioSciences from a “sell” rating to a “hold” rating and boosted their price target for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. Barclays lifted their price objective on shares of Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a report on Friday, February 28th. Needham & Company LLC upped their target price on shares of Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Royal Bank of Canada reiterated a “sector perform” rating and set a $18.00 price target on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Finally, HC Wainwright increased their price objective on Pacira BioSciences from $57.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $27.22.

Pacira BioSciences Price Performance

Pacira BioSciences stock opened at $24.14 on Friday. Pacira BioSciences, Inc. has a 52 week low of $11.16 and a 52 week high of $31.67. The company’s 50 day moving average price is $24.44 and its two-hundred day moving average price is $19.58. The stock has a market cap of $1.12 billion, a P/E ratio of -11.89 and a beta of 0.86. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.